USTR Launches Section 301 Investigation into Germany's Pharmaceutical Pricing Policies
核心洞察
The U.S. Trade Representative has initiated a Section 301 investigation into Germany (搜索) over alleged persistent underpayment for innovative pharmaceutical products.
The investigation follows months of bilateral discussions and concerns that Germany (搜索) is fast-tracking legislation to further reduce spending on innovative drugs.
USTR (搜索) argues that American patients bear a disproportionate share of global pharmaceutical R&D costs due to foreign pricing practices.
The United States Trade Representative (USTR (搜索)) has formally initiated a Section 301 investigation into Germany (搜索)'s pharmaceutical pricing policies, alleging that the country's persistent underpayment for innovative medicines is unreasonable, discriminatory, and burdens U.S. commerce. The announcement, made Thursday night by U.S. Trade Representative Jamieson Greer, marks a significant escalation in trade tensions and could ultimately lead to retaliatory tariffs on German goods.
"President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," said Ambassador Greer. "I am particularly concerned with news that Germany (搜索) is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals. This is a serious step backwards at a time when our trading partners need to step up and start paying their fair share to fund innovative pharmaceutical research and development."
The investigation follows months of what USTR (搜索) described as "meaningful discussions" with German partners aimed at resolving the pricing imbalance. Greer expressed optimism that a negotiated path forward remains possible, stating, "We believe that the United States and Germany (搜索) can find a path forward that expands access to the most innovative drugs for the German people while ensuring fair reimbursement for the pharmaceuticals made by American workers."
Presidential Directive and Policy Context
The Section 301 probe stems from a May 12, 2025 presidential directive instructing the U.S. Trade Representative to "take all necessary and appropriate action" to address foreign countries' unfair actions that have the "effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries."
Section 301 of the Trade Act of 1974, as amended, is designed to address unfair foreign practices affecting U.S. commerce. Under Section 302(b), the U.S. Trade Representative may self-initiate an investigation. The investigation will examine whether Germany (搜索)'s acts, policies, or practices are unreasonable or discriminatory and burden or restrict U.S. commerce.
Alleged Pricing Mechanisms Under Scrutiny
According to the Federal Register notice, the investigation focuses on Germany (搜索)'s pricing policies and practices regarding innovative pharmaceutical products. The USTR (搜索) identified several mechanisms that may contribute to payment disparities, including supplemental discounts offered in exchange for confidentiality of negotiated prices and mandatory variable rate rebates.
U.S.-UK Agreement as a Model
Greer pointed to the April 2, 2026 pharmaceutical pricing arrangement between the United States and the United Kingdom as a potential template for resolving the dispute. "Germany (搜索) should follow suit with constructive negotiations to address this imbalance," he said.
HHS Support
U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr. endorsed the investigation, framing the issue as one of shared global responsibility. "Fighting the war against disease is a shared burden across wealthy nations," Kennedy said. "The United States is calling on Germany (搜索) to pay its fair share for the innovative treatments its people use. I commend Ambassador Greer for his leadership in confronting this imbalance. Fair reimbursement strengthens medical innovation and helps ensure the development of the next generation of lifesaving cures."
Procedural Timeline
USTR (搜索) has requested consultations with Germany (搜索) in connection with the investigation. Interested persons must submit written comments and requests to appear at the public hearing by August 10, 2026. A public hearing is scheduled for September 22, 2026. Following the investigation and consideration of the inter-agency Section 301 Committee's advice, the USTR will determine whether action is warranted and what form any response should take.